Page 'Sub' Navigation:
Page Path 'Breadcrumb':
Development Pipeline
Phase 0 studies are microdose studies in humans conducted under an exploratory IND or clinical trial application*RDEA119 and our other MEK inhibitors are being developed under a global license agreement with Bayer HealthCare.
**The timing of future studies of our HIV compounds will be dependent on the results of future partnering efforts.
For more information regarding these programs please click here to view our most recent company presentation.